Compare MUJ & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MUJ | YDES |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.8M | 543.0M |
| IPO Year | 1998 | N/A |
| Metric | MUJ | YDES |
|---|---|---|
| Price | $12.27 | $2.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 90.0K | 33.6K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.66 | $2.14 |
| 52 Week High | $12.68 | $25.00 |
| Indicator | MUJ | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 48.31 | 31.91 |
| Support Level | $11.96 | N/A |
| Resistance Level | $12.43 | $5.36 |
| Average True Range (ATR) | 0.11 | 0.44 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 45.24 | 18.35 |
BlackRock MuniHoldings New Jersey Quality Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund mainly invests in long-term, investment-grade municipal obligations exempt from U.S federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and New Jersey personal income taxes, with remaining maturities of one year or more at the time of investment. The rest of its managed assets can be invested in securities that are rated below investment grade (or similar instruments), or invested directly in securities or synthetically through the use of derivatives.
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.